Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Takes Stock: Hayden To Head U.S. Rx After Lane Departs

Executive Summary

Bristol-Myers Squibb is turning to Exec VP Donald Hayden to restore the performance of - and confidence in - its U.S. pharmaceutical business

You may also be interested in...



SEC Hints At Further Charges In Bristol Case: Focus Shifts To Former Execs

The Securities & Exchange Commission's continuing investigation into Bristol-Myers Squibb's inventory accounting practices includes potential charges against "individuals responsible for the company's failures.

SEC Hints At Further Charges In Bristol Case: Focus Shifts To Former Execs

The Securities & Exchange Commission's continuing investigation into Bristol-Myers Squibb's inventory accounting practices includes potential charges against "individuals responsible for the company's failures.

Sanofi Plavix Inventory Rise Expected After Significant Q1 Destocking

Sanofi-Synthelabo expects wholesale levels of Plavix (clopidogrel) to climb following a "very large" destocking of the antithrombotic during the first quarter of 2003

Related Content

UsernamePublicRestriction

Register

PS039606

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel